Plain-English translation of NCT05781152 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This research study is following children who have just been diagnosed with Crohn's disease and are starting treatment with anti-TNF medications (like adalimumab or infliximab). The goal is to understand which children get complete healing of their intestines, and what factors — such as genes, immune responses, and gut bacteria — predict who will do well on this medication. By learning this, doctors hope to personalize treatment for future patients.
Crohn's disease damages the intestines, and while has helped many patients, not everyone heals completely. Researchers want to figure out why some children respond better than others, so doctors can predict outcomes and choose the best treatment for each child earlier.
You likely qualify if…
You likely don't qualify if…
You will start the medication your doctor recommends (typically an ) and come back for regular visits over about one year. During visits, you'll have blood tests, provide stool samples, and undergo imaging scans (like MRI) and endoscopy procedures to see how well your intestines are healing. Researchers will also collect information about your genes, immune system, and gut bacteria to understand what helps predict good outcomes.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States